Consensus EPS · Q2 2026
$2.30
Consensus revenue · Q2 2026
$19.6B
Analysts
11
Expected report
Aug 5, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 11 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $18.9B | $19.6B | $20.5B |
| EPS | $2.20 | $2.30 | $2.42 |
| EBITDA | $2B | $2.1B | $2.1B |
| EBIT | $1.8B | $1.9B | $1.9B |
| Net income | $1.4B | $1.5B | $1.6B |
- Revenue$19.6B
- EPS$2.30
- EBITDA$2.1B
- EBIT$1.9B
- Net income$1.5B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $19.1B | $19.5B | -2.1% | $2.42 | $2.27 | +6.5% |
| Q4 2025 | $24.2B | $27.2B | -11.1% | $2.49 | $2.34 | +6.6% |
- Q1 2026-2.1%+6.5%
- Q4 2025-11.1%+6.6%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for MetLife (MET) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 6 analysts.
- Low
- $90.00
- Consensus
- $98.22
- Median
- $96.00
- High
- $105.00
- Current
- $93.27
- Upside
- +5.3%
Upside calculated vs most recent trading price of $93.27.
Analyst ratings
Consensus: Buy — based on 33 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 21, 2026 | JP Morgan | maintain | Overweight | Overweight |
| Jul 13, 2026 | Keefe, Bruyette & Woods | maintain | Outperform | Outperform |
| Jul 13, 2026 | Evercore ISI Group | maintain | In Line | In Line |
| Jul 10, 2026 | Jefferies | maintain | Buy | Buy |
| Jul 9, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 9, 2026 | Mizuho | maintain | Outperform | Outperform |
| Jul 8, 2026 | UBS | maintain | Buy | Buy |
| Jul 7, 2026 | Barclays | maintain | Overweight | Overweight |
| Jul 6, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jun 24, 2026 | Piper Sandler | maintain | Neutral | Neutral |
- Jul 21, 2026JP MorganOverweight
- Jul 13, 2026Keefe, Bruyette & WoodsOutperform
- Jul 13, 2026Evercore ISI GroupIn Line
- Jul 10, 2026JefferiesBuy
- Jul 9, 2026Wells FargoOverweight
- Jul 9, 2026MizuhoOutperform
- Jul 8, 2026UBSBuy
- Jul 7, 2026BarclaysOverweight
- Jul 6, 2026Morgan StanleyOverweight
- Jun 24, 2026Piper SandlerNeutral
Frequently asked questions
MetLife (MET) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks4.83% TTM
- Dividend Profile2.46% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History1 split
How this company returns cash to shareholders — buybacks, dividends, and stock splits.